Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa

A.M. Jones, L. Martin, R.J. Bright-Thomas, M.E. Dodd, A McDowell, K.L. Moffitt, J.S. Elborn, A.K. Webb
European Respiratory Journal 2003 22: 503-506; DOI: 10.1183/09031936.03.00004503
A.M. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Martin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R.J. Bright-Thomas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.E. Dodd
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A McDowell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K.L. Moffitt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.S. Elborn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.K. Webb
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Chronic Pseudomonas aeruginosa infection in cystic fibrosis (CF) leads to a damaging host inflammatory response. There are an increasing number of reports of P. aeruginosa cross-infection at CF centres. The clinical significance of acquisition of a transmissible strain for patients who already harbour P. aeruginosa is unclear. In this study, levels of inflammatory markers in clinically stable adult CF patients who harbour transmissible and sporadic strains of P. aeruginosa have been compared.

Patients with CF and chronic P. aeruginosa infection were grouped into those who harbour a transmissible P. aeruginosa and those who harbour their own sporadic strains. Total white cell and differential counts, sputum neutrophil elastase (NE), interleukin (IL)‐8, tumour necrosis factor (TNF)‐α, plasma IL‐6 and NE/α1‐antitrypsin complexes, serum C‐reactive protein, and urine TNF receptor 1 were all measured in clinically stable patients 4–6 weeks following completion of intravenous antibiotic therapy.

The two groups (both n=20) were well matched for per cent predicted forced expiratory volume in one second, per cent predicted forced vital capacity and body mass index. There were no significant differences in levels of white cell counts or inflammatory markers between the two groups.

At times of clinical stability, cystic fibrosis patients infected with transmissible Pseudomonas aeruginosa do not have a heightened inflammatory response above that of those harbouring sporadic strains.

  • cross-infection
  • cystic fibrosis
  • inflammation
  • Pseudomonas aeruginosa

The major cause of morbidity and mortality for individuals with cystic fibrosis (CF) is pulmonary disease due tochronic infection and a damaging host inflammatory response. The major bacterial pathogen involved is Pseudomonas aeruginosa 1. Recently, there have been a number of reports of P. aeruginosa cross-infection outbreaks at CF centres and holiday camps 2–8. Isolates of many of the transmissible strains commonly exhibit unusual phenotypic features; morphotypes of the most prevalent transmissible strain at the Manchester Adult CF Centre, P. aeruginosa strain MA, are associated with an unusual pyocin type, are nonpigmented, nonmotile and are often resistant to the majority of usual anti-pseudomonal antibiotics 3. The clinical significance of acquisition of a transmissible strain for patients who already harbour their own sporadic strain ofP. aeruginosa is unclear, although some clinicians have reported an increase in morbidity 2, 8, 9 and mortality 2 among CF patients infected with a transmissible strain of P.aeruginosa.

Airway inflammation is a major factor in the pathogenesis of CF lung disease. Inflammatory mediators as markers of the host response to infection may reflect the intensity of lung injury and relate to changes in clinical status. When clinically stable, CF patients with chronic P. aeruginosa infection are known to have increased levels of inflammatory markers compared to the non‐CF population 10, 11. If transmissible strains of P. aeruginosa are more virulent they may provoke an enhanced inflammatory response. In this study, levels ofinflammatory markers in clinically stable adult CF patientswho harbour a transmissible P. aeruginosa have been compared with those harbouring sporadic strains of P.aeruginosa.

Methods

CF patients with chronic P. aeruginosa infection who attend the Manchester Adult CF Centre were invited to participate in the study if they were clinically stable (defined as an absence of new symptoms and stable pulmonary function) and had received a course of i.v. antibiotic treatment 4–6 weeks earlier. The course of i.v. antibiotic treatment was of at least 7 days duration and consisted of a combination of at least two different classes of intravenous anti-pseudomonal antibiotics. The in vitro sensitivity of the P.aeruginosa from the most recently available sputum isolate is used to guide antibiotic choice and adjusted where appropriate when a current culture is available. Approval for the study was given by South Manchester Research Ethics Committee and written informed consent was obtained from each patient.

Patients were grouped on the basis of results of prospective bacterial fingerprinting of P. aeruginosa isolates from sputa, as previously reported 3. Patients were grouped into those who have harboured a transmissible strain of P. aeruginosa (P. aeruginosa strain MA) for at ≥12 months and those whoharbour their own sporadic P. aeruginosa. The two groups were prospectively matched by per cent predicted forced expiratory volume in one second (%FEV1). Patients co-infected with Burkholderia cepacia complex or other transmissible strains of P. aeruginosa were excluded from the study. Baseline patient demographics in the study were age, sex, CF genotype, presence of pancreatic insufficiency and/or diabetes mellitus, and use of nebulised antibiotics, deoxyribonuclease, long-term oral macrolide antibiotics, inhaled corticosteroids, and oral corticosteroids. %FEV1, per cent predicted forced vital capacity (%FVC) and body mass index (BMI) were measured. The total duration of the previous course of i.v. antibiotics and time from completion to the study visit were recorded. The in vitro phenotypic appearance (nonmucoid or mucoid) and antibiotic sensitivity patterns of the P. aeruginosa isolates were noted. For thepurpose of this study, multiresistance was defined as resistance to two of the three major classes of usual antipseudomonal antibiotics (aminoglycosides, quinolones, β‐lactams). Antibiotic resistance was assessed by the British Society for Antimicrobial Chemotherapy standardised disc testing method. Susceptibility and resistance of isolates was based on standard breakpoint values for each antibiotic (British Society for Antimicrobial Chemotherapy).

A sample of whole blood was analysed the same day for total white cell and differential cell counts. Samples of sputum, urine, plasma and serum were obtained for measurement of inflammatory markers. Sputum was diluted weight for weight with 0.9% (weight/volume) saline in a 1:5 ratio, centrifuged at 3000×g for 30 min and the supernatant collected. All samples were stored in aliquots at −80°C pending the measurement of inflammatory mediators.

Inflammatory markers were analysed as a single batch byablinded investigator. The levels of the following markerswere measured: sputum neutrophil elastase (NE), interleukin (IL)‐8 and tumour necrosis factor (TNF)‐α, plasma IL‐6 andNE/α1‐antitrypsin complexes, serum C‐reactive protein (CRP), and urine TNF receptor 1. NE was detected by spectrophotometric assay, utilising the substrate N‐Methoxysuccinyl-Ala‐Ala‐Pro‐Val‐p‐nitroanilide. All other parameters were measured by commercially available enzyme-linked immunosorbent assays (ELISA), with the exception ofNE/α1‐antitrypsin complexes, which were detected byan ELISA developed within the authors' laboratory, andrelevant performance and quality control checks were conducted.

Statistical analysis

The baseline demographics of the two groups were compared by Chi‐squared and unpaired t‐tests. The differences in total white cell and neutrophil counts were analysed using a two-sample t‐test. Group differences in levels of inflammatory markers were assessed by the Mann‐Whitney U‐test.

Results

For the transmissible group there were 22 eligible patients (i.e. patients who had chronic infection with the transmissible P. aeruginosa strain MA for >12 months); 20 out of 22 patients were recruited. Two were not recruited, as they did not receive a course of i.v. antibiotics over the study period. The 20 patients with the transmissible strain were matched by %FEV1 with 20 CF patients harbouring sporadic P. aeruginosa. The two groups (sporadic versus transmissible P.aeruginosa strains) were well matched in terms of mean age, %FEV1, %FVC, BMI and demographic features (table 1⇓). Patients received i.v. antibiotic therapy for a median (range) of 14 (9–37) and 14 (8–28) days (p=0.68) in the sporadic and transmissible P. aeruginosa groups, respectively. The study visit was a mean (se) 35.8 (1.2) and 33.7 (0.9) days (p=0.20) after the final day of i.v. antibiotic treatment for the sporadic and transmissible P. aeruginosa groups, respectively. There were no differences between the sporadic and transmissible P.aeruginosa groups in median change in %FEV1 (−2.2 (−11.5–15.4) and −2.5 (−23.5–6.3); p=0.57), %FVC (−3.9 (−14.1–6.6) and −5.0 (−50.7–6.4); p=0.37) or BMI (0.15 (1.2–−1.3) and 0.15 (−0.8–1.2); p=0.36) from the end of the course of i.v. antibiotics to the study day.

View this table:
  • View inline
  • View popup
Table 1

Demographics of cystic fibrosis (CF) groups

Whole blood, plasma and serum samples were obtained from all patients. Two patients in the transmissible P. aeruginosa group were unable to produce a sputum sample. Two patients in the sporadic P. aeruginosa group were unable to produce a urine sample because of time restraints on the study day. The results of whole blood white cell and neutrophil counts and the levels of inflammatory markers are given in table 2⇓. There was no difference between the twogroups for the levels of white cell counts and the inflammatory markers.

View this table:
  • View inline
  • View popup
Table 2

White cell counts (WCC) and inflammatory markers in cystic fibrosis patients with chronic Pseudomonas aeruginosa (P. aeruginosa) infection

Discussion

This study examines differences in levels of inflammatory markers between two groups of clinically stable CF patients with chronic P. aeruginosa infection; those who harbour their own sporadic P. aeruginosa and those who harbour a transmissible strain (P. aeruginosa strain MA). There were no differences in levels of inflammatory markers between thetwo groups.

There are an increasing number of reports of P. aeruginosa cross-infection outbreaks among individuals with CF 2–7, 12. The significance of P. aeruginosa cross-infection and the provision of resources for microbiological surveillance and implementation of infection control measures remains controversial 13–16. Whilst new acquisition of P. aeruginosa bypreviously “Pseudomonas-naïve” CF patients is associated with a worsening of their clinical status 1, 17–21, the effect ofacquisition of a different strain for patients who already harbour P. aeruginosa is unclear. However, there are reasons for CF physicians to be concerned about transmissible strains of P. aeruginosa. Isolates belonging to transmissible strains of P. aeruginosa often exhibit unusual phenotypic characteristics 3, including in vitro antibiotic resistance 2, 3, 6. In the present study, a higher number (16 out of 20) of patients in the transmissible P. aeruginosa group were found to harbour a multi-resistant P. aeruginosa isolate than patients with sporadic strains (three out of 20) (p<0.001). Transmissible strains have also been associated with super-infection of CF patients who already harbour other P. aeruginosa 4. The authors have previously documented an increase in treatment requirements for adult CF patients who harbour a transmissible strain of P. aeruginosa 9. More worrying is a report from Nixon et al. 2 of an increased morbidity and mortality for CF children in association with P. aeruginosa cross-infection. A recent publication by Armstrong et al. 8 observed a lower %FEV1 among patients at a paediatric CF centre who harboured a transmissible P. aeruginosa; however, the two groups were not prospectively matched.

There is a current lack of published data as to whether transmissible P. aeruginosa are more virulent than sporadic strains, but such information is needed by CF clinicians. The current study was designed to investigate whether adult CF patients who harbour transmissible P. aeruginosa strain MA demonstrate a more florid host inflammatory response than those who harbour sporadic strains of P. aeruginosa. Patients with chronic P. aeruginosa infection experience episodes of respiratory exacerbations that are associated with a decrease in lung function and a systemic inflammatory response, with increased levels of inflammatory markers, including TNF‐α, NE/α1‐antitrypsin complexes, IL‐6, IL‐8 and CRP 11, 22–24. I.v. antibiotic therapy leads to a reduction in host inflammatory responses 11, 23. However, even at times of apparent clinical stability, CF patients with chronic P. aeruginosa infection still demonstrate increased levels of inflammatory markers indicating chronic inflammatory activity and accompanying lung injury 11, 24–26. The persistent inflammatory response to chronic pulmonary infection also leads to an increased resting energy expenditure and patient metabolism 23, adversely affecting nutritional status. If some strains of P. aeruginosa are more virulent they should be more likely to provoke an enhanced host inflammatory response. However, in this study, no differences in levels of inflammatory markers were shown between CF patients with infection by transmissible and sporadic strains of P. aeruginosa at times of clinical stability.

Although these findings provide a degree of reassurance forclinicians that care for CF patients who harbour transmissible P. aeruginosa, the study has a number of drawbacks. First, as the number of CF patients identified as harbouring transmissible P. aeruginosa is small, subjects for such studies are limited and it is, therefore, difficult to fully exclude a type‐2 error. Secondly, some patients who harbour the transmissible strain are co‐infected with a sporadic P. aeruginosa strain. However, although inclusion of these patients might bias results, particularly if a transmissible strain was less virulent, these subjects make the group more representative ofthe CFpatients in clinical practice. Thirdly, in addition tobacterial virulence factors, DNA polymorphisms in host genes regulating inflammatory responses to respiratory pathogens may influence levels of inflammatory markers 27. It is difficult both to assess and make allowances for such a potential confounding variable in an in‐vivo study. Finally, measuring levels of host inflammatory markers may not provide an accurate prediction of future clinical outcome. A previous study did not find a difference in levels of blood cytokines between CF patients with P. aeruginosa and B. cepacia complex 22, despite a well-recognised increased pathogenicity of B. cepacia complex in clinical practice 28,29. However, that study had smaller numbers of subjects andmeasured circulating inflammatory markers, which may not be as representative of inflammatory activity within the lung as those in bronchoalveolar lavage fluid or sputa. The present study recruited a greater number of patients andexamined inflammatory markers in sputa and the circulation.

In conclusion, at times of clinical stability, cystic fibrosis patients infected with transmissible Pseudomonas aeruginosa do not have a heightened inflammatory response above those who harbour sporadic strains. Further prospective studies are needed to assess the long-term clinical effects of spread of transmissible Pseudomonas aeruginosa strains among individuals with cystic fibrosis.

Acknowledgments

The authors would like to gratefully acknowledge the assistance of J.R.W. Govan, C.J. Doherty and the staff of Medical Microbiology, University of Edinburgh, UK, in typing of the P. aeruginosa isolates.

  • Received January 14, 2003.
  • Accepted May 8, 2003.
  • © ERS Journals Ltd

References

  1. ↵
    Cystic Fibrosis Foundation. Patient registry 1999 annual reportBethesda, MA, Cystic Fibrosis Foundation, 2000.
  2. ↵
    Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699–704.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Jones AM, Govan JR, Doherty CJ, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001;358:557–558.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P. aeruginosa. Lancet 2001;358:558–560.
    OpenUrlCrossRefPubMedWeb of Science
  5. Ojeniyi B, Frederiksen B, Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 2000;29:177–181.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Cheng K, Smyth RL, Govan JR, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348:639–642.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Hunfeld KP, Schmidt C, Krackhardt B, et al. Risk of Pseudomonas aeruginosa cross-colonisation in patients with cystic fibrosis within a holiday camp – a molecular-epidemiological study. Wien Klin Wochenschr 2000;112:329–333.
    OpenUrlPubMedWeb of Science
  8. ↵
    Armstrong DS, Nixon GM, Carzino R, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002;166:983–987.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Jones AM, Dodd ME, Doherty CJ, Govan JRW, Webb AK. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 2002;57:924–925.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995;152:2111–2118.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin‐6 in cystic fibrosis. Am J Respir Crit Care Med 1998;157:1764–1769.
  12. Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986;17:505–516.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Hoogkamp-Korstanje JA, Meis JF, Kissing J, van der Laag J, Melchers WJ. Risk of cross-colonization and infection by Pseudomonas aeruginosa in a holiday camp for cystic fibrosis patients. J Clin Microbiol 1995;33:572–575.
    OpenUrlAbstract/FREE Full Text
  14. Geddes DM. Of isolates and isolation: Pseudomonas aeruginosa in adults with cystic fibrosis. Lancet 2001;358:522–523.
    OpenUrlCrossRefPubMedWeb of Science
  15. Pitt TL. Cross infection of cystic fibrosis patients with Pseudomonas aeruginosa. Thorax 2002;57:921.
    OpenUrlFREE Full Text
  16. ↵
    Ramsay BW. To cohort or not to cohort: how transmissible is Pseudomonas aeruginosa?. Am J Respir Crit Care Med 2002;166:906–907.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Hudson VL, Wielinski CL, Regelmann WE. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J Pediatr 1993;122:854–860.
    OpenUrlPubMedWeb of Science
  18. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330–335.
    OpenUrlCrossRefPubMedWeb of Science
  19. Kosorok MR, Zeng L, West SE, et al. Acceleration of lungdisease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277–287.
    OpenUrlCrossRefPubMedWeb of Science
  20. Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990;116:714–719.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995;19:10–15.
    OpenUrlPubMedWeb of Science
  22. ↵
    Hendry J, Elborn JS, Nixon L, Shale DJ, Webb AK. Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa. Eur Respir J 1999;14:435–438.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Bell SC, Bowerman AM, Nixon LE, Macdonald IA, Elborn JS, Shale DJ. Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis. Eur J Clin Invest 2000;30:553–559.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Elborn JS, Cordon SM, Parker D, Delamere FM, Shale DJ. The host inflammatory response prior to death in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Respir Med 1993;87:603–607.
    OpenUrlCrossRefPubMedWeb of Science
  25. Brown MA, Morgan WJ, Finley PR, Scuderi P. Circulating levels of tumor necrosis factor and interleukin‐1 in cystic fibrosis. Pediatr Pulmonol 1991;10:86–91.
    OpenUrlPubMedWeb of Science
  26. ↵
    Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158–161.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    Hull J, Thomson AH. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 1998;53:1018–1021.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Jones AM, Dodd ME, Webb AK. Burkholderia cepacia: current clinical issues, environmental controversies and ethical dilemmas. Eur Respir J 2001;17:295–301.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970–1989. Am J Epidemiol 1996;143:1007–1017.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 22 Issue 3 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa
A.M. Jones, L. Martin, R.J. Bright-Thomas, M.E. Dodd, A McDowell, K.L. Moffitt, J.S. Elborn, A.K. Webb
European Respiratory Journal Sep 2003, 22 (3) 503-506; DOI: 10.1183/09031936.03.00004503

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa
A.M. Jones, L. Martin, R.J. Bright-Thomas, M.E. Dodd, A McDowell, K.L. Moffitt, J.S. Elborn, A.K. Webb
European Respiratory Journal Sep 2003, 22 (3) 503-506; DOI: 10.1183/09031936.03.00004503
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Cystic fibrosis neutrophils have normal intrinsic reactive oxygen species generation
  • Absorptive clearance of DTPA as an aerosol-based biomarker in the cystic fibrosis airway
  • Long-term effects of a partially supervised conditioning programme in cystic fibrosis
Show more Original Articles: Cystic Fibrosis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society